Cellular targets to overcome KRAS inhibitor resistance in pancreatic tumors identified

Cellular targets to overcome KRAS inhibitor resistance in pancreatic tumors identified

A study led by University of Cincinnati Cancer Center researchers sheds new light on how pancreatic cancer cells resist treatment and points to potential new combination therapies to make treatments more effective.

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer

To further determine genetic mechanisms of KRAS inhibitor (KRASi) resistance, scientists performed KRASi-anchored CRISPR-Cas9 loss-of-function screens in KRASG12D, KRASG12C, KRASG12R, and KRASQ61H mutant PDAC cell lines, using six KRASi, to identify genes that modulate sensitivity to KRAS inhibition. [Cancer Research] Abstract